The effect of 6-day subcutaneous glucose-dependent insulinotropic polypeptide infusion on time in glycaemic range in patients with type 1 diabetes: a randomised, double-blind, placebo-controlled crossover trial

被引:8
作者
Heimburger, Sebastian M. N. [1 ,2 ,3 ]
Hoe, Bjorn [1 ,4 ]
Nielsen, Chris N. [1 ]
Bergmann, Natasha C. [1 ]
Hartmann, Bolette [3 ,5 ]
Holst, Jens J. [3 ,5 ]
Vilsboll, Tina [1 ,2 ,4 ]
Dejgaard, Thomas F. [1 ,2 ]
Christensen, Mikkel B. [1 ,4 ,6 ,7 ]
Knop, Filip K. [1 ,2 ,3 ,4 ]
机构
[1] Univ Copenhagen, Gentofte Hosp, Ctr Clin Metab Res, Hellerup, Denmark
[2] Steno Diabet Ctr Copenhagen, Gentofte, Denmark
[3] Univ Copenhagen, Fac Hlth & Med Sci, Novo Nordisk Fdn Ctr Basic Metab Res, Copenhagen, Denmark
[4] Univ Copenhagen, Fac Hlth & Med Sci, Dept Clin Med, Copenhagen, Denmark
[5] Univ Copenhagen, Fac Hlth & Med Sci, Dept Biomed Sci, Copenhagen, Denmark
[6] Univ Copenhagen, Bispebjerg Hosp, Dept Clin Pharmacol, Copenhagen, Denmark
[7] Univ Copenhagen, Bispebjerg Hosp, Copenhagen Ctr Translat Res, Copenhagen, Denmark
关键词
Adipose tissue; Continuous glucose monitoring; GIP; Glucose-dependent insulinotropic polypeptide; Glycaemic control; Glycaemic time in range; Hypoglycaemia; Hypoglycaemic events; Insulin resistance; Insulin sensitivity; RECEPTOR AGONIST; GLUCAGON; HYPOGLYCEMIA; RESPONSES;
D O I
10.1007/s00125-021-05547-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims/hypothesis Type 1 diabetes is characterised by reduced glucagon response to hypoglycaemia, increasing the risk of insulin treatment-associated hypoglycaemia known to hamper glycaemic control. We previously reported a glucagonotropic effect of exogenous glucose-dependent insulinotropic polypeptide (GIP) during insulin-induced hypoglycaemia in individuals with type 1 diabetes. Here we investigate the effect of a 6-day s.c. GIP infusion on time in glycaemic range as assessed by continuous glucose monitoring (CGM) in individuals with type 1 diabetes. Methods In a randomised, placebo-controlled, double-blind crossover study, time in glycaemic range (assessed by double-blinded CGM) was evaluated in 20 men with type 1 diabetes (18-75 years, stable insulin treatment >= 3 months, diabetes duration 2-15 years, fasting plasma C-peptide below 200 pmol/l, BMI 20-27 kg/m(2), HbA(1c) <69 mmol/mol [8.5%]) during two x 6 days of continuous s.c. GIP (6 pmol kg(-1) min(-1)) and placebo (saline [154 mmol/l NaCl]) infusion, respectively, with an interposed 7-day washout period. The primary outcome was glycaemic time below range, time in range and time above range. Results There were no significant differences in time below range (<3.9 mmol/l, p = 0.53) or above range (>10 mmol/l, p = 0.32) during night-time or daytime, in mean glucose, or in hypoglycaemic events as assessed by CGM. GIP altered neither self-reported hypoglycaemia nor safety measures. Compared with placebo, GIP significantly increased time in tight range (3.9-7.8 mmol/l) during daytime (06:00-23:59 hours) by [mean +/- SEM] 11.2 +/- 5.1% [95% CI 0.41, 21.9] (p = 0.02). Conclusions/interpretation Six-day s.c. GIP infusion in men with type 1 diabetes did not procure convincing effect on overall time in range, but increased time in tight glycaemic range during daytime by similar to 2 h per day.
引用
收藏
页码:2425 / 2431
页数:7
相关论文
共 50 条
  • [31] The effect of ginger powder supplementation on insulin resistance and glycemic indices in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial
    Mozaffari-Khosravi, Hassan
    Talaei, Behrouz
    Jalali, Beman-Ali
    Najarzadeh, Azadeh
    Mozayan, Mohammad Reza
    COMPLEMENTARY THERAPIES IN MEDICINE, 2014, 22 (01) : 9 - 16
  • [32] EFFECT OF SITAGLIPTIN ON POSTPRANDIAL GLUCAGON AND GLP-1 LEVELS IN PATIENTS WITH TYPE 1 DIABETES: INVESTIGATOR-INITIATED, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL
    Garg, Satish K.
    Moser, Emily G.
    Bode, Bruce W.
    Klaff, Leslie J.
    Hiatt, William R.
    Beatson, Christie
    Snell-Bergeon, Janet K.
    ENDOCRINE PRACTICE, 2013, 19 (01) : 19 - 28
  • [33] Efficacy and safety of cetagliptin as monotherapy in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled phase 3 trial
    Ji, Linong
    Lu, Jinmiao
    Gao, Leili
    Ying, Changjiang
    Sun, Jiao
    Han, Jie
    Zhao, Wenhua
    Gao, Yunming
    Wang, Kun
    Zheng, Xin
    Xie, Daosheng
    Ding, Juping
    Zhao, Jiahong
    Yu, Qiang
    Wang, Tong
    DIABETES OBESITY & METABOLISM, 2023, 25 (12) : 3671 - 3681
  • [34] Effect of Crocus sativus Extract Supplementation in the Metabolic Control of People with Diabetes Mellitus Type 1: A Double-Blind Randomized Placebo-Controlled Trial
    Giannoulaki, Parthena
    Kotzakioulafi, Evangelia
    Nakas, Alexandros
    Kontoninas, Zisis
    Karlafti, Eleni
    Evripidou, Polykarpos
    Kantartzis, Konstantinos
    Savopoulos, Christos
    Chourdakis, Michail
    Didangelos, Triantafyllos
    NUTRIENTS, 2024, 16 (13)
  • [35] Hypoglycemic effect of camel milk powder in type 2 diabetic patients: A randomized, double-blind, placebo-controlled trial
    Zheng, Yajie
    Wu, Fang
    Zhang, Ming
    Fang, Bing
    Zhao, Liang
    Dong, Lijie
    Zhou, Xiaojuan
    Ge, Shaoyang
    FOOD SCIENCE & NUTRITION, 2021, 9 (08): : 4461 - 4472
  • [36] Does dapagliflozin regress left ventricular hypertrophy in patients with type 2 diabetes? A prospective, double-blind, randomised, placebo-controlled study
    Brown, Alexander J. M.
    Lang, Chim
    McCrimmon, Rory
    Struthers, Allan
    BMC CARDIOVASCULAR DISORDERS, 2017, 17
  • [37] Effect of the mineralocorticoid receptor antagonist eplerenone on liver fat and metabolism in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial (MIRAD trial)
    Johansen, Marie L.
    Schou, Morten
    Rossignol, Patrick
    Holm, Maria R.
    Rasmussen, Jon
    Brandt, Niels
    Frandsen, Mikkel
    Chabanova, Elizaveta
    Dela, Flemming
    Faber, Jens
    Kistorp, Caroline
    DIABETES OBESITY & METABOLISM, 2019, 21 (10) : 2305 - 2314
  • [38] Saffron improves life and sleep quality, glycaemic status, lipid profile and liver function in diabetic patients: A double-blind, placebo-controlled, randomised clinical trial
    Tajaddini, Aynaz
    Roshanravan, Neda
    Mobasseri, Majid
    Aeinehchi, Aydin
    Azar, Pouria Sefid-Mooye
    Hadi, Amir
    Ostadrahimi, Alireza
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2021, 75 (08)
  • [39] A randomised, double-blind, placebo-controlled trial of metformin on myocardial efficiency in insulin-resistant chronic heart failure patients without diabetes
    Larsen, Anders Hostrup
    Jessen, Niels
    Norrelund, Helene
    Tolbod, Lars Poulsen
    Harms, Hendrik Johannes
    Feddersen, Soren
    Nielsen, Flemming
    Brosen, Kim
    Hansson, Nils Henrik
    Frokiaer, Jorgen
    Poulsen, Steen Hvitfeldt
    Soerensen, Jens
    Wiggers, Henrik
    EUROPEAN JOURNAL OF HEART FAILURE, 2020, 22 (09) : 1628 - 1637
  • [40] Efficacy and safety of therapy with metformin plus pioglitazone in the treatment of patients with type 2 diabetes: a double-blind, placebo-controlled, clinical trial
    Kaku, Kohei
    CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (05) : 1111 - 1119